2,788 Shares in Humana Inc. $HUM Purchased by Aaron Wealth Advisors LLC

Aaron Wealth Advisors LLC acquired a new position in shares of Humana Inc. (NYSE:HUM) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,788 shares of the insurance provider’s stock, valued at approximately $725,000.

A number of other institutional investors also recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Humana by 16.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider’s stock valued at $300,728,000 after buying an additional 158,528 shares during the last quarter. Focus Partners Wealth raised its position in shares of Humana by 104.2% during the first quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider’s stock worth $1,701,000 after acquiring an additional 3,281 shares during the last quarter. Swedbank AB lifted its stake in shares of Humana by 5.3% during the second quarter. Swedbank AB now owns 100,397 shares of the insurance provider’s stock valued at $24,545,000 after acquiring an additional 5,032 shares during the period. Circle Wealth Management LLC bought a new position in Humana in the first quarter valued at about $425,000. Finally, Kera Capital Partners Inc. bought a new position in Humana in the second quarter valued at about $253,000. 92.38% of the stock is owned by institutional investors.

Humana Trading Up 0.8%

HUM opened at $260.25 on Thursday. The firm’s fifty day moving average is $260.48 and its two-hundred day moving average is $259.01. The firm has a market cap of $31.30 billion, a PE ratio of 24.39, a price-to-earnings-growth ratio of 1.51 and a beta of 0.46. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $315.35. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 2.02.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.29. The company had revenue of $32.65 billion during the quarter, compared to analyst estimates of $31.99 billion. Humana had a net margin of 1.02% and a return on equity of 12.86%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.16 EPS. Equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Friday, December 26th. Humana’s dividend payout ratio is 33.18%.

Analysts Set New Price Targets

HUM has been the subject of several recent research reports. Robert W. Baird dropped their price objective on Humana from $280.00 to $264.00 and set a “neutral” rating for the company in a report on Thursday, December 11th. KeyCorp reissued a “sector weight” rating on shares of Humana in a research note on Friday, December 12th. Guggenheim restated a “buy” rating on shares of Humana in a report on Friday, October 3rd. Evercore ISI began coverage on shares of Humana in a report on Monday, September 22nd. They set an “in-line” rating and a $295.00 target price for the company. Finally, Morgan Stanley dropped their target price on shares of Humana from $277.00 to $262.00 and set an “equal weight” rating for the company in a research report on Wednesday. Nine investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $294.32.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.